FindTrial
Sign In

Needling with adjunctive intravitreal injection of bevacizumab (avastin). A preliminary study.

Needling with adjunctive intravitreal injection of bevacizumab (avastin). A preliminary study.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-TRC-08000711
Enrollment
Unknown
Registered
2008-02-15
Start date
2008-02-21
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

1:Needling with intravitreal injection of Bevacizumab (Avastin) vs No control or comparative treatment for this study for 10 to 15min

Sponsors

None listed

Eligibility

Sex/Gender
Male
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 years or above; 2. Eyes that undergo needling; 3. Patient able and willing to give informed consent to needling with intra-vitreal injection of bevacizumab.

Exclusion criteria

Exclusion criteria: 1. Single functional eye; 2. Pregnant patients; 3. Patients refusing needling or bevacizumab injection; 4. Use of anticoagulants or antiplatelet therapy other than aspirin/NSAIDs within 14 days of surgery; 5. Presence of a nonhealing wound, ulcer, fracture, or any medical condition associated with bleeding.

Design outcomes

Primary

MeasureTime frame
Intraocular pressure;—

Secondary

MeasureTime frame
1. Bleb morphology (with photographic record) 2. Visual acuity 3. Number of IOP-lowering medications 4. Corneal clarity and corneal endothelial cell count (by specular microscopy) 5. Lens status 6. Progression in glaucomatous optic neuropathy and visual field loss 7. Any complications from surgery;—

Countries

China

Contacts

Public ContactProf. Dennis SC Lam
dennislam_cu_res@cuhk.edu.hk+852 27623134

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026